AdvanCell, a clinical-stage radiopharmaceutical company developing innovative cancer therapeutics, today announced the successful completion of an oversubscribed US$112 million Series C financing.
Editorial cartoons for Jan. 19, 2025: Trump’s second inaugural, Hegseth hearing, wildfire politics Note to Ohio lawmakers drafting energy bill - an all-of-the-above portfolio urgently needed: ...
America must act accordingly. “The test of a first-rate intelligence is the ability to hold two opposed ideas in mind at the same time and still retain the ability to function.” It’s an oft-referenced ...